Fubotv earnings beat by $0.10, revenue topped estimates
On Wednesday, Scotiabank (TSX:BNS) analyst Greg Harrison increased the price target for Liquidia Technologies (NASDAQ:LQDA) shares to $37.00, up from the previous $36.00, while maintaining a Sector Outperform rating. With a current market capitalization of $1.3 billion, LQDA has seen impressive momentum, gaining over 34% in the past six months. The adjustment follows the recent approval of Yutrepia™ for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
According to Harrison, Liquidia appears well-positioned for commercial success as the launch of Yutrepia™ progresses. InvestingPro data shows the company maintains a healthy current ratio of 2.93, indicating strong liquidity to support the launch. The management team’s follow-up call shed light on Yutrepia™’s comprehensive patient access programs, its flexible dosing options, and its competitive pricing, which matches that of Tyvaso DPI at $24,362 for a 28-day supply. These factors are anticipated to drive widespread adoption of the treatment.
Scotiabank’s analysis suggests that the market may be underestimating Yutrepia™’s potential impact on both PAH and PH-ILD, with projections for 2031 revenues at $1.03 billion compared to the consensus estimate of $754 million. This optimistic outlook is reflected in the broader analyst consensus, with targets ranging from $13 to $37. The firm also commends Liquidia’s patient access strategy, which is expected to attract new patients and facilitate the transition from Tyvaso. For deeper insights into LQDA’s growth potential and comprehensive financial analysis, check out the detailed Pro Research Report available on InvestingPro.
While some investors are concerned about the ongoing ’782 patent litigation with United, Harrison believes there is a minimal chance that legal proceedings will interfere with the commercial introduction of Yutrepia™. Scotiabank has updated its financial model to reflect the approval of Yutrepia™ and the anticipated early stages of its market introduction, leading to the revised price target. The report also includes a catalyst calendar for investors’ reference. With a moderate debt level and strong liquidity position, InvestingPro analysis indicates the company is well-positioned to execute its commercial strategy, though investors should note the current high revenue valuation multiple.
In other recent news, Liquidia Technologies has seen a flurry of activity with analysts adjusting their price targets and maintaining positive ratings on the company’s stock. Wells Fargo (NYSE:WFC) analyst Tiago Fauth increased Liquidia’s price target to $23, citing the company’s progress in overcoming regulatory and legal challenges. BTIG analyst Julian Harrison raised the price target to $37, highlighting expectations for the recently FDA-approved Yutrepia product to gain market traction. Jefferies analyst Kambiz Yazdi also lifted the target to $31, emphasizing Yutrepia’s approval for treating pulmonary arterial hypertension and its potential benefits for patients.
Raymond (NSE:RYMD) James maintained a Strong Buy rating with a $29 target, following Yutrepia’s final FDA approval. Analysts have noted that Liquidia’s management is preparing to commercialize Yutrepia, with expectations of reaching profitability in the near future. The company is also involved in ongoing litigation with United Therapeutics (NASDAQ:UTHR), but analysts like Harrison from BTIG see a low likelihood of significant legal setbacks affecting Liquidia. The collective analyst sentiment remains positive, with expectations that Liquidia will successfully navigate its current challenges and capitalize on market opportunities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.